Skip to main content
. Author manuscript; available in PMC: 2021 Jul 29.
Published in final edited form as: Am J Transplant. 2015 Mar 3;15(4):1014–1020. doi: 10.1111/ajt.13083

Figure 1: Titers of anti-BKV genotype Ia neutralizing antibodies in commercial preparations of human intravenous immunoglobulin (IVIG) and cytomegalovirus hyperimmune intravenous immunoglobulin (CMVIG).

Figure 1:

The x-axis depicts serial dilutions (log10) of IVIG and CMVIG added to the culture of 293TT cells exposed to BKV genotype Ia reporter vector. Luciferase release measured in relative light intensity units (RLUs) is plotted on the y-axis. Fifty percent inhibition (EC50) was obtained at a dilution of 1:51814 for IVIG and 1:18349 for CMVIG. Data is expressed as mean ± SE from triplicate wells of one representative experiment. The curves were plotted using Graph Pad Prism software.